MAPT and Alzheimer disease: In addition, the predicted P-tau/Aβ42 ratio was also compared between aMCI and Non-AD (0.76, P < 0.001, Fig. 7d), and AD and aMCI (0.72, P < 0.001, Fig. 7e).